Sign inThe amended 8-K adds fresh 2026 agreements between CDT Equity and Sarborg Limited, including share sales and a related-party patent assignment, atop previously disclosed 2025 results.
SEC filing
The all-stock deal would create a Nasdaq company advancing neridronate for CRPS-1, backed by an oversubscribed $150 million financing.
SEC filing
The company said it intends to buy back stock at $5.00 to $5.75 per share, funded by cash on hand, with the offer expected to run late August through late September 2026.
SEC filing
The divestiture delivered $7.7 million at closing, with the company's press release citing an $8 million closing figure and up to $3 million more in potential milestone payments.
SEC filing
The agreement transfers FreeT's stake in Apitox, including a domestic Korean market claim and royalty rights on U.S. and overseas proceeds.
SEC filing
The company entered a sales agreement on August 21, 2026 letting it sell shares over time to fund clinical development and other priorities.
SEC filing
The company disclosed that Nasim Shomali joined the Audit Committee effective August 18, 2026, completing details left open in a July board appointment filing.
SEC filing
The company could receive up to $50 million from Lincoln Park Capital under a purchase agreement, but only 8.9 million shares are being registered for resale now.
SEC filing
Vicore Pharma finished patient recruitment for its Phase 2b IPF trial ahead of schedule and began trading its ADSs on Nasdaq Capital Market in July.
SEC filing
The company filed a prospectus supplement dated August 21, 2026, expanding the amount it can sell through its at-the-market agreement with Roth Capital Partners.
SEC filing
The deal funds $150 million in committed capital plus warrants worth up to $100 million more if seralutinib wins FDA approval in PAH.
SEC filing
TuHURA Biosciences borrowed $650,000 on August 7, 2026 and another $650,000 on August 20, 2026 under its revolving credit facility with Parkview Holdings One LLC.
SEC filing (3)
The company's August 21 amendment clarifies that director Michael Grissinger joined the Compensation Committee on August 18, 2026, with added annual pay for the role.
SEC filing
The filing covers shares issuable from Series D preferred stock sold under a $25 million purchase agreement signed July 31, 2026 with Ault Lending, LLC.
SEC filing
The deal covers proposed biosimilars to Imfinzi and Hemlibra in the U.S. and eight Asian markets, with potential value to Alvotech of up to about $150 million.
SEC filing
The company keeps its WTX-124 and WTX-330 clinical programs through a new license from EMD while non-clinical assets change hands.
SEC filing
Interim results show the oral drug candidate was well tolerated and reached the brain, with a cardiovascular risk cohort now dosing and full data due in H1 2027.
SEC filing
The company expects roughly $471.7 million in net proceeds to fund a potential avexitide launch in post-bariatric hypoglycemia, with an NDA planned by year-end 2026.
SEC filing (2)
Investors elected seven directors, approved executive pay on an advisory basis, and raised director compensation limits at the August 20, 2026 meeting.
SEC filing
The neurorehabilitation company added three directors and lost four board members within days of reporting stronger quarterly sales and a planned CFO transition.
SEC filing (2)
Trial dropout rate is running lower than expected as Sol-Gel advances new studies in high-frequency BCC and Mohs surgery neo-adjuvant use.
SEC filing
A Form D filing shows the company sold equity tied to a business combination transaction, with 44 investors participating.
SEC filing
Senti Holdings, a subsidiary of Senti Biosciences Holdings, sold additional senior secured convertible notes to Celadon Partners SPV 24 under an existing April 2026 agreement.
SEC filing
The company reported $215.9 million in cash and gave updated timelines for its two lead programs, givastomig and VIS-101.
SEC filing
Scienture Holdings reported the commercial start of its second product, new patents on both approved drugs, and expanded payer coverage alongside its quarterly financials.
SEC filing
The company expects net proceeds of about $471.7 million to help fund a potential U.S. launch of avexitide.
SEC filing
The consumer health company added its first film and television ambassador as it lifted 2026 revenue guidance and issued a first 2027 forecast.
SEC filing
The company amended terms tied to its Sanity Group acquisition and named two executives to lead an integrated Canada-Europe platform.
SEC filing
Bicycle Therapeutics plc disclosed that Charles Swanton left his board seat and advisory role on August 18, 2026, citing personal reasons.
SEC filing
The S-1 resale filing adds detail on a proposed Nasdaq market-value listing standard that the SEC approved and then paused pending review.
SEC filing